Trials / Withdrawn
WithdrawnNCT00168051
Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A
A Single Dose, Randomized, 2-Period Crossover Study in Patients With Hemophilia A to Evaluate the Pharmacokinetics of ReFacto (B-domain Deleted Recombinant Human Factor VIII (BDDrFVIII) and Advante (a Full-length Recombinant Factor VIII (FLrFVIII)
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- Male
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to compare the pharmacokinetic parameters of ReFacto and Advate, using the chromogenetic substrate assay to measure plasma Factor VIII activity in plasma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ReFacto | |
| DRUG | Advante |
Timeline
- Start date
- 2005-04-01
- Primary completion
- 2005-11-01
- Completion
- 2005-11-01
- First posted
- 2005-09-14
- Last updated
- 2018-09-25
Locations
13 sites across 8 countries: United States, Belgium, France, Germany, Italy, Netherlands, New Zealand, United Kingdom
Source: ClinicalTrials.gov record NCT00168051. Inclusion in this directory is not an endorsement.